交易中 11-04 10:06:59 美东时间
-0.050
-0.05%
HAMPTON, N.H., Oct. 30, 2025 /PRNewswire/ -- Planet Fitness, Inc. (NYSE: PLNT) (the "Company"), today announced that the Company will host an Investor Day for investors and research analysts...
10-30 20:00
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
10-28 10:08
HAMPTON, N.H., Oct. 27, 2025 /PRNewswire/ -- Planet Fitness, Inc. (NYSE: PLNT) (the "Company"), one of the largest and fastest-growing franchisors and operators of fitness centers with more ...
10-27 20:30
Planet Fitness and Hockey Canada announced a three-year partnership, with Planet Fitness becoming the official fitness partner of Hockey Canada. The collaboration also involves National Women’s Team players Natalie Spooner, Emily Clark, and Emma Maltais, who will promote fitness and wellness through social media, in-club activations, and community events. Planet Fitness, known for its Judgement Free Zone® concept, offers affordable memberships wi...
10-21 12:30
HAMPTON, N.H., Oct. 20, 2025 /PRNewswire/ -- Planet Fitness, Inc. (NYSE: PLNT) (the "Company"), one of the largest and fastest-growing franchisors and operators of fitness centers with more ...
10-21 04:05
今日重点评级关注:韦德布什:维持Artiva Biotherapeutics"跑赢大市"评级,目标价从18美元升至23美元;巴克莱:维持Cellectis"超配"评级,目标价从4美元升至8美元
10-20 10:03
华尔街最受关注、且可能影响市场走势的研究评级报告现已汇总如下。以下是由 The Fly 整理的今日投资者需关注的重点评级动态。 五大评级上调 瑞银集团...
10-17 22:29
Planet Fitness (NYSE:PLNT) has outperformed the market over the past 10 years b...
10-14 23:15
Planet Fitness partners with BGC Canada to support youth well-being and foster kind communities through a nationwide fundraising campaign in Canadian clubs from October 1-31. The initiative includes creating Judgement Free Zones with quality equipment and mental wellness support. Free PF Black Card memberships are offered to 2025 BGC Canada Youth of the Year honorees, promoting inclusive fitness spaces. Planet Fitness also offers an October sale ...
10-01 12:30
今日重点评级关注:Benchmark:维持Unicycive Therapeutics"投机性买入"评级,目标价从3美元升至21美元;Guggenheim:维持Amylyx Pharmaceuticals"买入"评级,目标价从17美元升至25美元
09-16 09:48